TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04662580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX517
Description: ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX517
Description: ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX517
Description: ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Oral tablet and will be given once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Oral tablet and will be given once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
Study: NCT06518525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates-based tele-exercises
Description: pilates-based tele-exercises
Study: NCT04925752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir (LEN)
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir (LEN)
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-cutaneous (SC) Lenacapavir (LEN)
Description: Administered via SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-cutaneous (SC) Lenacapavir (LEN)
Description: Administered via SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC LEN
Description: Administered via SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM F/TDF
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM Oral LEN
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (for US participants only)
Description: F/TAF tablets administered orally once daily
Study: NCT05091671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free From Pain Exercise Programme Variation 1
Description: Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
Study: NCT05037994

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine
Description: The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine
Description: The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap.
Study: NCT05091671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free From Pain Exercise Programme Variation 2
Description: Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
Study: NCT01600807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Erlotinib, OSI-906
Description: Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Erlotinib
Description: Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
Study: NCT05252065

Intervention type: OTHER
Intervention: Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging
Description: Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
Study: NCT06491979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A treatment
Description: Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid mixture
Description: Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid mixture
Description: Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks
Study: NCT06569745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Explanation
Description: In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation Video Display
Description: In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Led Reels Video Display
Description: In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
Study: NCT05942222

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dupilumab
Description: Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dupilumab
Description: Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dupilumab
Description: Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mepolizumab
Description: Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mepolizumab
Description: Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
Study: NCT06494072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin for Injection
Description: Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin for Injection
Description: Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone for Injection
Description: Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone for Injection
Description: Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study: NCT05681949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADBoard
Description: Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
Study: NCT05345158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Retroperitoneal Lymph Node Dissection (RPLND)
Description: Robotic RPLND performed using the DaVinci robotic surgical system.
Study: NCT04704843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as IV infusion (induction dose) and SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as IV infusion (induction dose) and SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
Study: NCT04623398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04208464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg daily for 24 weeks from baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
Study: NCT05895864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
Study: NCT06494072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin / Sulbactam Injection
Description: Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin / Sulbactam Injection
Description: Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil
Description: Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefprozil
Description: Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Study: NCT06302062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Associated Lymph node T cell
Description: At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
Study: NCT06300684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Description: This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
Study: NCT06410131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTL008.16
Description: IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTL008.16
Description: IV infusion every 2 weeks
Study: NCT06126705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation: 18F-AlF-FAPi-04
Description: Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
Study: NCT05725434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47 AI (tocilizumab)
Description: CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47 PFS (tocilizumab)
Description: CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
Study: NCT05868473

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobilization With Movement
Description: Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kinesotaping
Description: Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
Study: NCT05314075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Body Forced Air Warming device
Description: Patients will have the Bair Hugger placed over the body

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Under Body Forced Air Warming device
Description: Patients will have the Bair Hugger placed under the body
Study: NCT05682443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given as IV infusion, Q6W, for up to 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses.
Description: lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses.
Description: lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
Study: NCT06214325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
Study: NCT06468943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: 1.8mg/kg/21d（d0） Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg bid PO（d0-d20）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/㎡/21d（d0） Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/㎡/21d（d1） Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/㎡/21d（d1） Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg PO （d1-d5）/21d
Study: NCT05043831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSLT
Description: Direct-SLT is applied via the limbus to the trabecular meshwork

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSLT
Description: Direct-SLT is applied via the limbus to the trabecular meshwork
Study: NCT06126705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation: 18F-AlF-FAPi-04
Description: Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation: 18F-FDG
Description: Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
Study: NCT05533372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: IA-14069 for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: IA-14069 for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: IA-14069 for oral administration.
Study: NCT06410404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus thoracis plane block
Description: with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus thoracis plane block
Description: with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
Study: NCT05533372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate for oral administration.